EW 8-K
Edwards Lifesciences Corp (EW)
8-K
2026-05-08
For: 2026-05-07
View Original
Added on
May 08, 2026
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) May 7, 2026
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) | (Commission file number) | (IRS Employer Identification No.) | ||||||||||||
(Address of principal executive offices and zip code)
(949 ) 250-2500
(Registrant's telephone number, including area code)
| N/A | ||
(Former name or former address, if changed since last report) | ||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Approval of the Amended and Restated Long-Term Stock Incentive Compensation Program
At the 2026 Annual Meeting of Stockholders (the “Annual Meeting”) of Edwards Lifesciences Corporation, a Delaware Corporation (the “Company”), the Company’s stockholders approved the amendment and restatement of the Company’s Long-Term Stock Incentive Compensation Program (the “Long-Term Stock Program”). The amendment approved by stockholders included an increase in the total number of shares of Edwards common stock available for issuance under the Long-Term Stock Program by 7,000,000 shares to a new total share limit of 341,500,000 shares.
The complete terms of the Long-Term Stock Program amendment is qualified in its entirety by reference to the full text of the Amended and Restated Long-Term Stock Program, which is filed as Exhibit 10.1 to this Current Report on Form 8-K.
Item 5.07 Submission of Matters to a Vote of Security Holders
The final results of voting for each matter submitted to a vote of stockholders at the Annual Meeting, which was held on May 7, 2026, are as follows:
Proposal 1: All the nominees for director listed in Proposal 1 were elected to serve until the Company’s next annual meeting of stockholders and until their respective successors are duly elected and qualified as set forth below:
| Nominee | For | Against | Abstain | Broker Non-Votes | ||||||||||
| Leslie C. Davis | 461,819,765 | 13,184,241 | 881,733 | 27,211,476 | ||||||||||
| David T. Feinberg, MD | 473,746,144 | 1,812,520 | 327,076 | 27,211,476 | ||||||||||
| Kieran T. Gallahue | 457,045,403 | 18,518,195 | 322,142 | 27,211,476 | ||||||||||
| Leslie S. Heisz | 454,955,195 | 20,567,869 | 362,676 | 27,211,476 | ||||||||||
| Paul A. LaViolette | 428,701,646 | 45,445,276 | 1,738,817 | 27,211,476 | ||||||||||
| Steven R. Loranger | 446,216,434 | 28,909,945 | 759,361 | 27,211,476 | ||||||||||
| Ramona Sequeira | 474,260,552 | 1,295,682 | 329,506 | 27,211,476 | ||||||||||
| Nicholas J. Valeriani | 441,224,095 | 34,327,820 | 333,825 | 27,211,476 | ||||||||||
| Bernard J. Zovighian | 459,179,727 | 16,257,009 | 449,004 | 27,211,476 | ||||||||||
Proposal 2: The advisory proposal regarding the Company’s named executive officer compensation was approved as set forth below:
| For | Against | Abstain | Broker Non-Votes | ||||||||
| 424,961,639 | 50,924,101 | 0 | 27,211,476 | ||||||||
Proposal 3: Ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 was approved as set forth below:
| For | Against | Abstain | Broker Non-Votes | ||||||||
| 446,283,142 | 56,814,075 | 0 | 27,211,476 | ||||||||
2
Proposal 4: The approval of the Company’s Amended and Restated Long-Term Stock Incentive Compensation Program was approved as set forth below:
| For | Against | Abstain | Broker Non-Votes | ||||||||
| 456,675,201 | 19,210,539 | 0 | 27,211,476 | ||||||||
Item 9.01 Financial Statements and Exhibits
(d) Exhibits.
| Exhibit No. | Description | |||||||
| 10.1 | ||||||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | |||||||
3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
EDWARDS LIFESCIENCES CORPORATION | ||||||||||||||
| By: | /s/ Linda J. Park | |||||||||||||
| Linda J. Park | ||||||||||||||
| Date: May 8, 2026 | Senior Vice President, Associate General Counsel, and Corporate Secretary | |||||||||||||
4